Fennec Pharmaceuticals (FENC) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Fennec Pharmaceuticals

NasdaqCM•Healthcare•Biotechnology

$12.45+0.06(<0.01%)Pre-market

Market Cap

$370.32M

P/S

6.3x

P/B

8.7x

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

How this company scores

GoodMetricSide Score: 61/100

Strongest: Growth (18/25); weakest: Cash & Earnings Quality (11/25).

Profitability17/25

Growth18/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality11/25

Strengths

Growing revenueLong cash runwayInterest easily coveredProfit converts from growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 51.9x5y range 49.4x – 51.9x

P/S · 6.3x5y range 2.6x – 795.5x

Currently near its 16-quarter median.

P/B · 8.7x5y range 5.3x – 48.5x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 5 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $370.32M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $59.22M
Q. Revenue: $17.87M
TTM EBITDA: $-1.12M
TTM Op. Income: $-1.12M
Q. Op. Income: $1.74M
TTM Net Income: $-3.25M
Q. Net Income: $1.97M
EPS: $0.06
Shares Out.: $34.55M

$59.22M in TTM revenue grew 77.8% YoY, reaching $17.87M last quarter. TTM EBITDA of $-1.12M and TTM operating income of $-1.12M show growth is flowing through to the bottom line. However, net income is negative at $3.25M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 5 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 9.7%
Op. Margin: 9.7%
Net Margin: 11.0%

Op. margin of 9.7% is up 38.0% YoY — cost efficiency is improving. Net margin at 11.0% Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 6.3x
P/B Ratio: 8.7x

P/S of 6.3x and P/B of 8.7x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $75.75M
Cash: $41.25M
Long-Term Debt: N/A
Book Value: $42.44M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $50,000
TTM Free Cash Flow: $-2.04M
FCF Margin: -3.4%
FCF / Net Income: 0.6

TTM FCF of $-2.04M on $50,000 in operating cash flow. The FCF / Net Income ratio of 0.6x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.